Personalis to Participate in Immuno Series US Virtual Meeting
15 10월 2020 - 10:02PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the company’s participation at the
Immuno Series US Virtual meeting which will be held online, October
15-16, 2020.
Personalis will present “Maximizing immunotherapy biomarker
discovery with a multidimensional tumor immunogenomics platform,”
featuring the Personalis universal cancer immunogenomics approach,
ImmunoID NeXT™. Kedar Hastak, PhD, will present for Personalis. His
presentation will focus on the current challenges facing
investigators in immuno-oncological translational research
including maximizing data generation from a single sample and the
analysis of complex data.
Dr. Hastak will discuss how more accurate, predictive biomarker
analysis may assist in the selection of effective combinatorial
immunotherapy treatments for patients. Additionally, the complexity
of both the tumor and tumor microenvironment suggests a
comprehensive approach is needed for robust characterization of the
cancer ecosystem. By combining highly sensitive, exome-scale DNA
and RNA sequencing with advanced analytics, the ImmunoID NeXT
Platform® provides a multidimensional view of the tumor and the
tumor microenvironment (TME) from a single sample preparation. Dr.
Hastak will feature a case study demonstrating the ability of this
immunogenomics profiling platform to uncover tumor escape
mechanisms and to identify composite biomarkers of potentially
greater predictive capacity from patients treated with immune
checkpoint blockade. Additionally, the presentation will highlight
NeXT Liquid Biopsy™, an exome-wide liquid biopsy approach combined
with ImmunoID NeXT, to further explore critical areas of tumor
biology.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veteran Program (VA MVP). In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform, Personalis’ services for the VA MVP,
the company’s business opportunities, leadership or growth, or
other future events. Such forward-looking statements involve risks
and uncertainties, including those related to the COVID-19
pandemic, that could cause actual results to differ materially from
any anticipated results or expectations expressed or implied by
such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including the company’s most
recent reports on Forms 8-K, 10-K and 10-Q, and include those
listed under the caption “Risk Factors.” Personalis disclaims any
obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201015005396/en/
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024